Journal article
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer
Abstract
Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1) gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) crizotinib. Current best practice guidelines recommend that all advanced stage non-squamous NSCLC patients be also tested for ROS1 gene rearrangements. Several studies have suggested that ROS1 immunohistochemistry (IHC) using the D4D6 antibody may be used to screen for ROS1 …
Authors
Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz J-C; Huang W-Y; Ionescu D; Itani D
Journal
Lung Cancer, Vol. 160, , pp. 127–135
Publisher
Elsevier
Publication Date
October 2021
DOI
10.1016/j.lungcan.2021.08.003
ISSN
0169-5002